{
  "disease_name": "Leishmaniasis",
  "disease_id": "leishmaniasis",
  "pathogen_type": "parasite",
  "pathogen": "Leishmania spp.",
  "target_classes": [
    "trypanothione_reductase",
    "topoisomerase_II",
    "CYP51",
    "miltefosine_transporter"
  ],
  "primary_endpoints": [
    "parasitological_cure_rate",
    "initial_cure_rate_6_months",
    "relapse_rate_12_months",
    "splenic_parasite_clearance"
  ],
  "efficacy_threshold": 0.65,
  "ic50_max_um": 10.0,
  "ic50_optimal_um": 1.0,
  "selectivity_index_min": 10.0,
  "cc50_min_um": 50.0,
  "toxicity_threshold": 0.021,
  "molecular_weight_max": 500.0,
  "logp_min": 0.0,
  "logp_max": 5.0,
  "hbd_max": 5,
  "hba_max": 10,
  "lipinski_violations_max": 1,
  "admet_score_min": 0.6,
  "prv_eligible": true,
  "regulatory_pathway": "PRV_ACCELERATED",
  "constraint_version": "2.0.0",
  "constitutional_compliance": {
    "L51_zero_gaps": true,
    "L10_harm_absolute": true,
    "L9_axiomatic_grounding": true,
    "L5_transparency": true,
    "L11_toxicity_hard_limit": true
  },
  "category": "tropical",
  "molecular_constraints": {
    "mw_min": 150,
    "mw_max": 500.0,
    "logp_min": 0.0,
    "logp_max": 5.0,
    "hbd_max": 5,
    "hba_max": 10,
    "tpsa_max": 140,
    "rotatable_bonds_max": 10,
    "toxicity_max": 0.021
  },
  "target_profile": {
    "pathogen_type": "parasite",
    "mechanism_classes": [
      "antiparasitic"
    ],
    "tissue_targets": [
      "blood",
      "liver",
      "skin"
    ]
  },
  "clinical_requirements": {
    "route": [
      "oral"
    ],
    "patient_population": "Adults and children in endemic regions",
    "treatment_setting": "outpatient"
  },
  "regulatory": {
    "fda_pathway": "PRV",
    "guidance_document": null,
    "orphan_eligible": true
  }
}
